Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

Keynote webinar | Spotlight on medication adherence

LIVE: Thursday 27th June 2024, 18:00-19:30 (CEST)
Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.
ADVANCED SEARCH
Log in
Top
Cardiovascular Drugs and Therapy
Published in: Cardiovascular Drugs and Therapy 5/2009

Open Access 01-10-2009 | Letter to the Editor

Ischaemic Preconditioning and Postconditioning do not Affect Adenosine A1 and A2A Receptor Sensitivity

Authors: Niels P. Riksen, Abigail Wynne, Derek M. Yellon, Derek J. Hausenloy

Published in: Cardiovascular Drugs and Therapy | Issue 5/2009

Login to get access

Excerpt

To the Editor: …
Literature
1.
Solenkova NV, Solodushko V, Cohen MV, Downey JM. Endogenous adenosine protects preconditioned heart during early minutes of reperfusion by activating Akt. Am J Physiol Heart Circ Physiol. 2006;290:H441–9.CrossRefPubMed
2.
Morrison RR, Tan XL, Ledent C, Mustafa SJ, Hofmann PA. Targeted deletion of A2A adenosine receptors attenuates the protective effects of myocardial postconditioning. Am J Physiol Heart Circ Physiol. 2007;293:H2523–9.CrossRefPubMed
3.
Kin H, Zatta AJ, Lofye MT, Amerson BS, Halkos ME, Kerendi F, et al. Postconditioning reduces infarct size via adenosine receptor activation by endogenous adenosine. Cardiovasc Res. 2005;67:124–33.CrossRefPubMed
4.
Goto M, Miura T, Iliodoromitis EK, et al. Adenosine infusion during early reperfusion failed to limit myocardial infarct size in a collateral deficient species. Cardiovasc Res. 1991;25:943–9.CrossRefPubMed
5.
Vander Heide RS, Reimer KA. Effect of adenosine therapy at reperfusion on myocardial infarct size in dogs. Cardiovasc Res. 1996;31:711–8.CrossRefPubMed
6.
Budde JM, Velez DA, Zhao Z, et al. Comparative study of AMP579 and adenosine in inhibition of neutrophil-mediated vascular and myocardial injury during 24 h of reperfusion. Cardiovasc Res. 2000;47:294–305.CrossRefPubMed
7.
Kuno A, Critz SD, Cui L, et al. Protein kinase C protects preconditioned rabbit hearts by increasing sensitivity of adenosine A2B-dependent signaling during early reperfusion. J Mol Cell Cardiol. 2007;43:262–71.CrossRefPubMed
8.
Gamboa A, Ertl AC, Costa F, et al. Blockade of nucleoside transport is required for delivery of intraarterial adenosine into the interstitium: relevance to therapeutic preconditioning in humans. Circulation. 2003;108:2631–5.CrossRefPubMed
Metadata
Title
Ischaemic Preconditioning and Postconditioning do not Affect Adenosine A1 and A2A Receptor Sensitivity
Authors
Niels P. Riksen
Abigail Wynne
Derek M. Yellon
Derek J. Hausenloy
Publication date
01-10-2009
Publisher
Springer US
Published in
Cardiovascular Drugs and Therapy / Issue 5/2009
Print ISSN: 0920-3206
Electronic ISSN: 1573-7241
DOI
https://doi.org/10.1007/s10557-009-6196-1

Other articles of this Issue 5/2009

Cardiovascular Drugs and Therapy 5/2009 Go to the issue

OriginalPaper

Respiratory Effects of β-blocker Therapy in Heart Failure

OriginalPaper

Anti-apoptotic Effects of a Calpain Inhibitor on Cardiomyocytes in a Canine Rapid Atrial Fibrillation Model

OriginalPaper

Comparison of the Effects of Levosimendan and Papaverine on Human Internal Mammary Artery and Saphenous Vein

EditorialNotes

Calpain in Atrial Fibrillation: Friend or Foe?

Editorial

A Clinical Puzzle: Fibrates and Homocysteine Elevation

OriginalPaper

How Can We Improve the Management of Vascular Risk in Type 2 Diabetes: Insights from FIELD

ACC 2024 Congress Coverage

Year in Review: Heart failure and cardiomyopathies

Heart Failure Video

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.

Watch now

Semaglutide benefits people with type 2 diabetes and obesity-related heart failure

16-04-2024 Type 2 Diabetes News

Incentivised to exercise

11-04-2024 Lifestyle Modifications News

New intervention for STEMI-related cardiogenic shock

10-04-2024 Myocardial Infarction News

» View more highlights on the ACC 2024 congress hub page

Image Credits